SCHEMBL26195686

SCHEMBL26195686

Cc1nnc(-c2cnn(C)c2C)o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.44
▸ NOTUM Q6P988 1/20 0.36
▸ BRD4 O60885 3/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ KDM4E B2RXH2 4/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ AXL P30530 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ MERTK Q12866 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ CASP3 P42574 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SENP8 Q96LD8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26195610 0.80 CYP11B2 (0.40) CYP11B2KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL31595830 0.78 CYP11B2 (0.39) CYP11B2BRD4KDM4ESMN1; SMN2MEN1
SCHEMBL26777691 0.77 MAPT (0.42) CYP11B2KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL26765907 0.74 CYP11B2 (0.40) CYP11B2BRD4KDM4EALDH1A1AXL
SCHEMBL26195683 0.74 DRD2 (0.36) NOTUM
SCHEMBL21233163 0.73 TSHR (0.44) CYP11B2NOTUMKDM4ESMN1; SMN2ALDH1A1
SCHEMBL26776554 0.71 CYP11B2 (0.38) CYP11B2BRD4KDM4EALDH1A1CREBBP
SCHEMBL21233161 0.69 CYP11B2 (0.39) CYP11B2BRD4KDM4ESMN1; SMN2ALDH1A1
SCHEMBL21233282 0.69 KDM4E (0.43) CYP11B2BRD4KDM4EALDH1A1CREBBP
SCHEMBL31595983 0.68 CYP11B2 (0.36) CYP11B2BRD4KDM4ESMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
WO-2023164235-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365592-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 CYP11B2 668/4885NOTUM 1909/4885BRD4 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback